MedX Announces Final Closing of Non-Brokered Private Placement
MWN-AI** Summary
MedX Health Corp. (TSX-V: MDX) has successfully completed the final closing of its Non-Brokered Private Placement, which was initially announced on February 25, 2025. Following previous announcements regarding interim closings, the final closing raised an additional $607,500 by issuing 8,678,571 units, bringing the total proceeds from the placement to approximately $2.06 million. Each unit consists of one common share and one share purchase warrant, with warrants allowing for the purchase of additional shares at $0.09 over the next year.
Notably, insiders participated in this placement, contributing $500,000 for 7,142,857 units. To comply with regulations, the company has invoked exemptions from formal valuation and minority shareholder approval under Multilateral Instrument 61-101, citing that the proposed placement's value does not exceed 25% of its market capitalization. Additionally, qualified agents received commissions totaling $15,880 and issued 226,857 agent's warrants, enabling further investments at predetermined prices.
The funds raised will support the ongoing development of MedX's SIAscopy® technology on its DermSecure® telemedicine platform, facilitate its entry into the occupational health market, and assist with general corporate initiatives. MedX focuses on skin health solutions, offering advanced devices that allow non-invasive imaging of moles and lesions, which are crucial for timely medical evaluations. Its products, cleared by relevant health authorities including Health Canada and the FDA, leverage patented technology to enhance dermatological assessments.
For further information, please visit MedX Health's official website, and note that neither the TSX Venture Exchange nor its Regulation Services Provider is responsible for the content of this release.
MWN-AI** Analysis
MedX Health Corp. (TSX-V: MDX) has recently concluded its final Closing of a Non-Brokered Private Placement, raising a significant total of $2,063,500. The company issued 29,478,571 Units at a price of $0.07 per Unit, which comprises one common share and one share purchase warrant, exercisable at $0.09 for one year. This capital infusion is pivotal as it aims to enhance MedX's innovative SIAscopy® telemedicine platform intended for skin health assessment, alongside bolstering its presence in the occupational health marketplace.
The participation of insiders, who contributed $500,000 towards 7,142,857 Units, signals confidence in the company's trajectory. Insider investment can be a positive indicator, suggesting that those closest to the company anticipate robust future performance. Furthermore, the inclusion of the Agent’s Warrants can incentivize agents to promote company shares, potentially increasing investor interest.
From a market perspective, investors should keep an eye on how the deployment of the raised capital influences MedX's operational capabilities and revenue stream growth. Given the stringent regulatory framework guiding such private placements (notably MI 61-101), MedX appears to be maneuvering within prudent governance, which may further solidify shareholder trust.
Considering the hold period of four months and one day for the securities issued, short-term fluctuations may occur, particularly as the market digests this new capital initiative. However, with MedX's focus on expanding its product offerings and market scope, as well as addressing rising demands for telehealth solutions post-pandemic, the medium- to long-term outlook remains favorable.
In conclusion, while caution is warranted over the initial trading period following the private placement, MedX Health Corp. seems well-positioned for growth, making it a candidate for consideration by investors looking at innovative healthcare technology firms. Analyzing performance metrics post-capital deployment will be crucial for assessing ongoing market viability.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MedX Health Corp. (“ MedX ” or the “ Company ”) (TSX-V: MDX ) is pleased to announce that, further to its Press Releases dated April 7, and May 22, 2025, announcing an Initial Closing and further Closing, it has completed a final Closing of the Non-brokered Private Placement to accredited investors originally announced in its Press Release dated February 25, 2025. The Final Closing comprised the issuance of 8,678,571 Units (as described below) and raised cash proceeds of $607,500, bringing the total amount raised in the Placement to $2,063,500. Securities issued are subject to a regulatory “hold” period of four months and one day from the date of issuance. Under this Non-Brokered Private Placement, the Company issued a total of 29,478,571 Units at $0.07 per Unit (“Unit”). Each Unit is comprised of One (1) fully paid common share and One (1) Share Purchase Warrant (“ Warrant ( s )”), exercisable to purchase One (1) further Common Share at the price of $0.09, during the period of one year commencing on the date of issuance. Three Insiders participated in this Placement to the extent of $500,000, for the acquisition of a total of 7,142,857 Units. In connection with the issuance of Units to those Insiders, the Company relies on exemptions from formal valuation and minority shareholder approval requirements set out in Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“ MI 61-101 ”). as (i) the fair market value of the proposed placement to the Insiders does not exceed 25% of the market capitalization of the Company and (ii) the conditions in section 5.7(1)(a), section 5.7(1)(b) and section 5.7(1)(e) of MI 61-101 are met.
Qualified agents received total cash commissions of $15,880, (equal to 8% of the gross proceeds received by the Company from the sale of the Units to subscribers introduced by such agent(s)), and 226,857 agent’s warrants (“ Agent’s Warrant(s) ”) (equal to 8% of subscriptions introduced by such agent(s)). Each Agent’s Warrant, which is non-transferable, entitles the holder to acquire, at the price of CAD$0.07, a unit, comprised of One (1) fully paid Common Share and one (1) non-transferable share purchase warrant (“ Agent’s Share Purchase Warrant ”), entitling the holder to acquire one additional Common Share at the price of CAD$0.09. The Agent’s Warrants and any Agent’s Share Purchase Warrants that may be issued pursuant to exercise of an Agent’s Warrant, if not exercised, will expire one year following the date of issuance.
Funds raised in this Placement are being be directed towards continuing development of the Company’s leading edge SIAscopy® on DermSecure® telemedicine platform, building out the launch of its technology into the occupational health marketplace, and general corporate purposes.
About MedX Health Corp.:
MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union and Turkey. Visit https://medxhealth.com .
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250609640146/en/
MedX Health Corp.
Mike Druhan, President, Dermatological Services
mike.druhan@medxhealth.com
(+1) 905-599-7852
FAQ**
How does the recent funding raise of $2,063,500 from the non-brokered private placement affect MedX Health Corp. MDX:CC's plans for further developing the SIAscopy® technology and its integration into the occupational health marketplace?
Given the participation of insiders in the private placement amounting to $500,000, what impact does this have on investor confidence in MedX Health Corp. MDX:CC's future performance and corporate governance?
Can you elaborate on the specific use of funds raised through the private placement and how they will contribute to the overall growth strategy of MedX Health Corp. MDX:CC in the competitive medical device sector?
What are the key benefits and value propositions of MedX Health Corp. MDX:CC’s SIAscopy® technology over existing skin health solutions, and how does the company plan to communicate these advantages to potential clients in the marketplace?
**MWN-AI FAQ is based on asking OpenAI questions about MedX Health Corp. (TSXVC: MDX:CC).
NASDAQ: MDX:CC
MDX:CC Trading
0.0% G/L:
$0.065 Last:
6,000 Volume:
$0.06 Open:
